RGNX · XBRL financial data

REGENXBIO financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RGNX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	155	470	113	90	83	170
Cost of goods and services sold	36	52	55	37	34	—
Research and development	166	181	242	232	209	228
General and administrative	64	79	85	88	77	83
Operating income (loss)	(119)	160	(263)	(268)	(233)	(161)
Interest income	—	—	6	9	12	12
Interest expense	1	26	23	7	13	45
Income tax expense (benefit)	5	13	(0)	(0)	0	0
Net income (loss)	(111)	128	(280)	(263)	(227)	(194)
Earnings per share, basic USD per share	(2.98)	3.01	(6.50)	(6.02)	(4.59)	(3.76)
Earnings per share, diluted USD per share	(2.98)	2.91	(6.50)	(6.02)	(4.59)	(3.76)
Weighted average shares, basic millions of shares	37	42	43	44	50	52
Weighted average shares, diluted millions of shares	37	44	43	44	50	52

Fiscal years (RGNX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	338	345	97	35	58	34
Marketable securities	137	112	268	241	177	196
Marketable securities, non-current	47	392	201	39	10	11
Accounts receivable	43	32	28	25	20	26
Total current assets	531	519	416	335	278	281
Property and equipment, net	56	132	142	132	118	105
Right-of-use asset	64	61	65	60	54	47
Total assets	708	1,114	833	574	466	453
Accounts payable	11	11	27	23	23	21
Total current liabilities	81	130	130	130	103	118
Lease liability, non-current	70	85	89	82	74	65
Total liabilities	330	350	317	262	206	350
Accumulated deficit	(289)	(161)	(442)	(705)	(932)	(1,126)
Total stockholders' equity	378	764	516	312	260	103
Total liabilities and equity	708	1,114	833	574	466	453
Common shares outstanding (cover page) millions of shares	42	43	43	44	50	52

Fiscal years (RGNX's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(111)	128	(280)	(263)	(227)	(194)
Stock-based compensation	32	39	41	40	38	35
Net cash from operating activities	(54)	219	(207)	(218)	(173)	(124)
Purchases of property and equipment	27	84	31	10	2	2
Net cash from investing activities	123	(407)	(12)	191	103	(16)
Net cash from financing activities	200	195	(29)	(35)	93	117
Net change in cash	269	7	(248)	(62)	23	(23)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
REGENXBIO	36	108	(62)*	66.0M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Cronos Group	467	53	24*	368.4M	—	Q2 FY26 10-QJun 30, 2026
CytomX Therapeutics	17	1.4	(18)*	217.9M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Capricor Therapeutics	21	not reported	(31)*	58.1M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Oruka Therapeutics	268	not reported	(33)*	66.2M	26.4 quarters	Q2 FY26 10-QJun 30, 2026
Cryoport	269	49	1.1*	50.6M	—	Q2 FY26 10-QJun 30, 2026
CytoDyn	16	not reported	(7.7)	1.5B	2.1 quarters	Q1 FY27 10-QAug 31, 2026
Emergent BioSolutions	176	110	100*	51.4M	—	Q3 FY26 10-QSep 30, 2026
Northwest Biotherapeutics	0.6	0.8	(7.2)*	1.7B	0.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.